Erickson L C
Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153.
Semin Cancer Biol. 1991 Aug;2(4):257-65.
The marginal level of clinical responses to the Chloroethylnitrosoureas (CENU, i.e. BCNU, CCNU, MeCCNU) suggests that there may exist an innate mechanism of resistance in tumors to these chemotherapeutic agents. A decade of research from many laboratories around the world has led to the identification of the mechanisms for tumor cell resistance to the CENU. The ability to prevent the formation of DNA interstrand crosslinks, thought to be the critical lethal lesion induced by these agents, is accomplished in a majority of human tumors by the unique DNA repair protein O-6 methylguanine DNA methyltransferase (MGMT). This review addresses the identification of this mechanism of resistance to therapy, and chemotherapeutic strategies to inhibit this DNA repair system, in an attempt to sensitize resistant tumors to the CENU.
对氯乙基亚硝脲类药物(CENU,即卡莫司汀、洛莫司汀、司莫司汀)的临床反应处于边缘水平,这表明肿瘤对这些化疗药物可能存在一种内在的耐药机制。世界各地许多实验室经过十年的研究,已确定了肿瘤细胞对CENU的耐药机制。防止DNA链间交联形成的能力被认为是这些药物诱导的关键致死性损伤,在大多数人类肿瘤中,这种能力是通过独特的DNA修复蛋白O-6甲基鸟嘌呤DNA甲基转移酶(MGMT)实现的。本综述阐述了这种治疗耐药机制的确定,以及抑制这种DNA修复系统的化疗策略,以期使耐药肿瘤对CENU敏感。